Eli Lilly and Company (SNSE:LLYCL)

Market Cap	624.23T
Revenue (ttm)	49.60T
Net Income (ttm)	12.85T
Shares Out	n/a
EPS (ttm)	14,243.07
PE Ratio	48.57
Forward PE	25.78
Dividend	5,545.25 (0.78%)
Ex-Dividend Date	Aug 15, 2025

Volume	1
Average Volume	29
Open	722,500
Previous Close	n/a
Day's Range	722,500 - 722,500
52-Week Range	608,400 - 940,500
Beta	n/a
RSI	47.78
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: LLYCL

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD